Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials

  • Wang, Wei-Lan (Department of Pharmaceutical Care, Chinese PLA General Hospital) ;
  • Tang, Zhi-Hui (Department of Pharmaceutical Care, Chinese PLA General Hospital) ;
  • Xie, Ting-Ting (Department of Pharmaceutical Care, Chinese PLA General Hospital) ;
  • Xiao, Bing-Kun (Department of pharmacochemistry, Institute of Radiation Medicine) ;
  • Zhang, Xin-Yu (Department of Pharmacy, Bengbu Medical University) ;
  • Guo, Dai-Hong (Department of Pharmaceutical Care, Chinese PLA General Hospital) ;
  • Wang, Dong-Xiao (Department of Pharmaceutical Care, Chinese PLA General Hospital) ;
  • Pei, Fei (Department of Pharmaceutical Care, Chinese PLA General Hospital) ;
  • Si, Hai-Yan (Department of Oncology, Chinese PLA General Hospital) ;
  • Zhu, Man (Department of Pharmaceutical Care, Chinese PLA General Hospital)
  • Published : 2014.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Many clinical trials have been conducted to evaluate sorafenib for the treatment of advanced NSCLC, but the results for efficacy have been inconsistent. The aim of this study was to evaluate the efficacy and safety of sorafenib in patients with advanced NSCLC in more detail by meta-analysis. Methods: This meta-analysis of randomized controlled trials (RCTs) was performed after searching PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, and the proceedings of major conferences for relevant clinical trials. Two reviewers independently assessed the quality of the trials. Outcomes analysis were disease control rate (DCR), progression- free survival (PFS), overall survival (OS) with 95% confidence intervals (CI) and major toxicity. Subgroup analysis was conducted according to sorafenib monotherapy, in combination with chemotherapy or EGFR-TKI to investigate the preferred therapy strategy. Results: Results reported from 6 RCTs involving 2, 748 patients were included in the analysis. Compared to sorafenib-free group, SBT was not associated with higher DCR (RR 1.31 (0.96- 1.79), p=0.09), PFS (HR 0.82 (0.66-1.02), p=0.07) and OS (HR 1.01 (0.92-1.12), p=0.77). In terms of subgroup results, sorafenib monotherapy was associated with significant superior DCR and longer PFS, but failed to show advantage with regard to OS. Grade 3 or greater sorafenib-related adverse events included fatigue, hypertension, diarrhea, oral mucositis, rash and HFSR. Conclusions: SBT was revealed to yield no improvement in DCR, PFS and OS. However, sorafenib as monotherapy showed some activity in NSCLC. Further evaluation may be considered in subsets of patients who may benefit from this treatment. Sorafenib combined inhibition therapy should be limited unless the choice of platinum-doublet regimen, administration sequence or identification of predictive biomarkers are considered to receive better anti-tumor activity and prevention of resistance mechanisms.

Keywords

References

  1. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 14, 7367-9. https://doi.org/10.7314/APJCP.2013.14.12.7367
  2. Blau HM, Banfi A (2001). The well-tempered vessel. Nat Med, 7, 532-4. https://doi.org/10.1038/87850
  3. Blumenschein GR Jr, Saintigny P, Liu S, et al (2013). Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res, 19, 6967-75 https://doi.org/10.1158/1078-0432.CCR-12-1818
  4. Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-57 https://doi.org/10.1038/35025220
  5. de Marinis F, Grossi F (2008). Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist, 13 Suppl 1, 14-20
  6. Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 56, 125-34
  7. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.10 [Internet]. Lyon, France: International Agency for Research on Cancer. Available: http://www. globocan. iarc.fr. Accessed 16 January 2012.
  8. Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74 https://doi.org/10.1038/nature04483
  9. Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov, 6, 273-86. https://doi.org/10.1038/nrd2115
  10. Hauschild A, Agarwala SS, Trefzer U, et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 27, 2823-30 https://doi.org/10.1200/JCO.2007.15.7636
  11. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60 https://doi.org/10.1136/bmj.327.7414.557
  12. Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials, 17, 1-12 https://doi.org/10.1016/0197-2456(95)00134-4
  13. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300 https://doi.org/10.3322/caac.20073
  14. Kemmer K, Corless CL, Fletcher JA, et al (2004). Kit mutations are common in testicular seminomas. Am J Pathol, 164, 305-13 https://doi.org/10.1016/S0002-9440(10)63120-3
  15. Kindler T, Lipka DB, Fischer T (2010). Flt3 as a therapeutic target in aml: still challenging after all these years. Blood, 116, 5089-102 https://doi.org/10.1182/blood-2010-04-261867
  16. Li J, Pan YY, Zhang Y (2013). Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. Oncol Lett, 5, 440-6.
  17. Lind JS, Dingemans AM, Groen HJ, et al (2010). A multicenter phase II study of erlotinib and sorafenib in chemotherapynaive patients with advanced non-small cell lung cancer. Clin Cancer Res, 16, 3078-87. https://doi.org/10.1158/1078-0432.CCR-09-3033
  18. Llovet JM, Ricci S, Mazzaferro V, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90 https://doi.org/10.1056/NEJMoa0708857
  19. Maurer G, Tarkowski B, Baccarini M (2011) Raf kinases in cancer-roles andtherapeutic opportunities. Oncogene, 30, 3477-88 https://doi.org/10.1038/onc.2011.160
  20. Metro G, Minotti V, Crino L (2012). Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? J Thorac Dis, 4, 635-8.
  21. Molina JR, Dy GK, Foster NR, et al (2011). A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol, 29, (suppl; abstr 7513).
  22. Paz-Ares L, Hirsh V, Zhang L, et al (2012). Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebocontrolled MISSION trial (abstract). Ann Oncol, 23, 33. https://doi.org/10.1093/annonc/mds086
  23. Paz-Ares LG, Biesma B, Heigener D, et al (2012). Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the firstline treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol, 30, 3084-92. https://doi.org/10.1200/JCO.2011.39.7646
  24. Plastaras JP, Kim SH, Liu YY, et al (2007). Cell cycle dependent and schedule- dependent antitumor effects of sorafenib combined with radiation. Cancer Res, 67, 9443 54.
  25. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH (2006). Paclitaxel- carboplatin alone or with bevacizumab for nonsmall- cell lung cancer. N Engl J Med, 355, 2542-50 https://doi.org/10.1056/NEJMoa061884
  26. Scagliotti G, Novello S, von Pawel J, et al (2010). Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 28, 1835-42. https://doi.org/10.1200/JCO.2009.26.1321
  27. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8 https://doi.org/10.1056/NEJMoa011954
  28. Spigel DR, Burris HA 3rd, Greco FA, et al (2011). Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 29, 2582-9. https://doi.org/10.1200/JCO.2010.30.7678
  29. Takezawa K, Okamoto I, Yonesaka K, et al (2009). Sorafenib inhibits non small cell lung cancer cell growth by targeting B RAF in KRAS wild type cells and C RAF in KRAS mutant cells. Cancer Res, 69, 6515-21. https://doi.org/10.1158/0008-5472.CAN-09-1076
  30. Wakelee HA, Lee JW, Hanna NH, et al (2012). A double- blind randomized discontinuation phase-ii study of sorafenib (BAY 43- 9006) in previously treated non-small-cell lung cancer patients: Eastern Cooperative Oncology Group Study E2501. J Thorac Oncol, 7, 1574-82. https://doi.org/10.1097/JTO.0b013e31826149ba
  31. Wilhelm SM, Adnane L, Newell P, et al (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf, VEGF and PDGF receptor signaling. Mol Cancer Ther, 7, 3129-40. https://doi.org/10.1158/1535-7163.MCT-08-0013
  32. Wilhelm SM, Carter C, Tang L, et al. (2004). Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109. https://doi.org/10.1158/0008-5472.CAN-04-1443

Cited by

  1. Sorafenib: 10 years after the first pivotal trial vol.11, pp.13, 2015, https://doi.org/10.2217/fon.15.85
  2. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC) vol.95, pp.50, 2016, https://doi.org/10.1097/MD.0000000000005599